EGFR and non-small cell lung carcinoma: The finding that specific mutated alleles of a single gene may impact immunotherapy efficacy in different manners is not unexpected; for instance, in a 2019 retrospective study, it was observed that outcomes of PD-L1 blockade were worse in NSCLC patients harboring mutations in exon 19 of EGFR, but not with the L858R variant in exon 21, compared with EGFR wt patients.